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Abstract
Activation of the insulin- like growth factor-1 receptor
( IGF-1R) by IGF-1 is associated with the risk and
progression of many types of cancer, although despite
this it remains unclear how activated IGF-1R contrib-
utes to cancer progression. In this study, gene expres-
sion changes elicited by IGF-1 were profiled in breast
epithelial cells. We noted that many genes are function-
ally linked to cancer progression and angiogenesis. To
validate some of the changes observed, the RNA and/or
protein was confirmed for c- fos, cytochrome P450 1A1,
cytochrome P450 1B1, interleukin-1 beta, fas ligand,
vascular endothelial growth factor, and urokinase
plasminogen activator. Nuclear proteins were also
temporally monitored to address how gene expression
changes were regulated. We found that IGF-1 stimu-
lated the nuclear translocation of phosphorylated AKT,
hypoxic- inducible factor-1 alpha, and phosphorylated
cAMP-responsive element-binding protein, which cor-
related with temporal changes in gene expression. Next,
the promoter regions of IGF-1–regulated genes were
searched in silico. The promoters of genes that
clustered together had similar regulatory regions. In
summary, IGF-1 inscribes a gene expression profile
relevant to cancer progression, and this study provides
insight into the mechanism(s) whereby some of these
changes occur.
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Introduction
The insulin- like growth factor -1 ( IGF-1) and its receptor
( IGF-1R) are associated with many types of human cancers,
including those derived from lung, breast, and prostate.
Based upon several epidemiological studies, elevated levels
of serum IGF-1 are linked to an increased risk of developing
ductal carcinoma in situ (DCIS) [1 ], as well as invasive
breast [2 ], colon [3], lung [4], and prostate cancers [5 ].
These data suggest that IGF-1/ IGF-1R is potentially a
useful molecular target for cancer intervention. In support of
this idea, there are several reports demonstrating that the
disruption of serum IGF-1 slows tumorigenesis. For exam-
ple, mice with reduced serum IGF-1 have slower-growing
tumors compared with wild - type mice [6]. We also showed
that attenuation of IGF-1 suppresses the progression of
bladder cancer in mice [7]. The importance of activated IGF-
1R in cancer progression is further underscored by its role in
cellular transformation [8] and maintenance of the malignant
phenotype. To illustrate this point, the malignant phenotype is
disrupted by antisense expression plasmids [9], antisense
oligodeoxynucleotides [10], a neutralizing antibody [11], and
dominant negative mutants to the IGF-1R [12]. Our
laboratory also demonstrated that inhibition of IGF-1R with
a dominant negative mutant suppresses invasion and
metastases of breast cancer in nude mice [13]. More
recently, it was reported that antisense oligodeoxynucleo-
tides to IGF-1R caused regression of astrocytomas in
humans [14]. These studies collectively point toward IGF-
1/ IGF-1R as being important for the development and
progression of a number of types of cancer. Thus, disrupting
IGF-1R or one of its critical signal transduction pathways
could have applications for cancer intervention.
IGF-1 binds to IGF-1R and triggers a cascade of signal
transduction events, including activation of the phosphatidyl
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inositol -3 kinase (PI3K) pathway that leads to phosphor-
ylation of AKT (P-AKT), rendering it in an active conforma-
tion. PI3K stimulates the P-AKT through either the integrin -
linked kinase [15] or phosphoinositide-dependent kinase
[16]. Upon activation, P-AKT rapidly responds to the IGF-1
signal by initially associating with the plasma membrane
where it binds to phosphatidylinositol 3,4,5-Tris phosphate
or phosphatidylinositol 3,4 bisphosphate [17]. Thereafter,
P-AKT leaves the plasma membrane and quickly trans-
locates into the nucleus [18]. Inhibition of PI3K signaling with
LY294002 inhibits the nuclear translocation of P-AKT and
correlates with a suppression of cell proliferation [19]. AKT is
also widely recognized for the ability to inhibit apoptosis as a
cellular response to insulin [20]. Furthermore, we previously
reported that IGF-1/AKT signaling facilitates cancer inva-
sion [21] while several other laboratories find that AKT is
important for the regulation of angiogenesis ( reviewed in
Ref. [22] ). AKT regulates angiogenesis in part by stimulating
the hypoxic - inducible factor -1 alpha (HIF-1 ) and the
subsequent production of the vascular endothelial growth
factor (VEGF) [23]. It is noteworthy that both hypoxia and
IGF-1 induce the nuclear accumulation of HIF-1 [24].
Hence, AKT is becoming a common intermediate in the
regulation of angiogenesis by controlling transcription factors
such as HIF-1.
AKT is a serine/ threonine kinase with the propensity to
regulate cellular processes by phosphorylating transcription
factors, thereby serving as a nuclear messenger for
controlling IGF-1–induced gene expression (Figure 1 ).
P-AKT binds and phosphorylates transcription factors such
as cAMP-responsive element binding (CREB), FKHRL1,
AFX, and NFkB. There is also evidence that activation of
AKT signaling by insulin stimulates activating protein-1
(AP-1) transactivation by inhibiting glycogen synthase
kinase-3 [25]. In the case of CREB, AKT binds this
transcription factor, resulting in phosphorylation of serine
133 [26]. The phosphorylation of CREB is sufficient for its
association with the coactivators CREB-binding protein
(CBP)/p300 and for transactivation of CRE-responsive
genes such as c- fos [27]. CREB becomes phosphorylated
by a variety of cellular stimuli, including hypoxia [28] and
IGF-1 [29]. The phosphorylation of CREB by hypoxia
depends upon AKT [30]. Hence, activation of HIF-1,
CREB, and AP-1 by AKT positively regulates gene
expression. Alternatively, AKT negatively regulates gene
expression in some cases by phosphorylating the forkhead
transcription factors FKHR, FKHRL1, and AFX. AKT
negatively regulates the mRNA expression of fas ligand
and the insulin -binding protein-1 by phosphorylating
FKHRL1 [31] and AFX [32], respectively. The phosphor-
ylation of FKHRL1 and AFX results in transport of these
transcription factors out of the nuclear compartment, and the
suppression of genes that positively regulate apoptosis.
Thus, AKT is emerging as an important molecule for
mediating nuclear transcription factors and the regulation
of gene expression by stimuli such as IGF-1.
A question that remains unanswered is how the IGF-1/
IGF-1R facilitates cancer progression because carcino-
genesis is a complex process that involves the stimulation
of cell growth signals, suppression of apoptosis, and the
acquisition of a malignant phenotype. With the advent of
microarrays and bioinformatics, we are poised to begin to
decipher such a complex biological problem. In this study, we
made temporal comparisons using the immortalized breast
epithelial cell 184htert and analyzed changes in gene
expression by microarray. We selected the 184htert cell line
because it loosely represents a preneoplastic stage of breast
cancer. Profiling a cell line such as the 184htert has a
recognizable distinction to other microarray reports where
normal and cancer cell lines were compared [33]. Given the
clinical, basic, and epidemiological support for IGF-1/ IGF-
1R in breast cancer, we recognized a need for defining the
influence of IGF-1 at an early stage with the hope of finding
avenues for intervention. Therefore, the model provided an
opportunity for studying the effect of IGF-1 on early stage of
breast cancer progression. The activation of oncogenes, loss
of tumor suppressor genes, and genomic instability asso-
ciated with breast cancer cell lines may confound our ability
to measure the effect of IGF-1 on the regulation of gene
expression. In this study, we found that IGF-1 induces
several genes involved in cancer progression particularly
those related to angiogenesis. Furthermore, we report that
IGF-1 stimulated the nuclear translocation of P-AKT, and
the transcription factors HIF-1 and cAMP-responsive
element-binding protein (P-CREB). These nuclear events
were correlated with the expression of genes that depend
upon CREB and HIF-1. In addition, we searched the
promoters of IGF-1–regulated genes in an attempt to find
common molecular features that could explain why temporal
Figure 1. A schematic representation of IGF -1 signal transduction leading
from the IGF -1R receptor to the eventual regulation of gene expression by P -
AKT. The activation of AKT by phosphorylation by phosphatidyl inositide -
dependent kinase (PDK) or integrin - linked kinase ( ILK ) results in localization
to the plasma membrane followed by trafficking into the nucleus. P -AKT
modifies the transcription activation of nuclear proteins by phosphorylating
them at serine and threonine residues. As a result of AKT phosphorylation,
transcription factors such as CREB, HIF -1, AP -1, and NFB are activated;
therefore, binding of these transcription factors induces gene expression.
Alternatively, the forkhead transcription factors (FKHR, FHKRL1, and AFX )
are phosphorylated by AKT at serine and threonine residues, although in this
case transactivation is inhibited because the modified proteins are expelled
from the nucleus.
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expression patterns occurred. We describe a temporal
correlation between distinct transcription-binding sites and
temporal gene expression regulated by IGF-1. The coupling
of gene expression profiling and the analysis of promoter
regulatory regions may provide insight into the underlying
mechanism of how other genes in the cluster are induced or
repressed.
Materials and Methods
Cell Lines
The 184htert cell line was created by the introduction of a
retrovirus expressing the human telomerase reverse tran-
scriptase gene into normal breast epithelial cells (184)
obtained from Dr. Martha Stampfer. We maintained the
184htert (generous gift from Dr. Toshi Tahara) in MEMB
(Clonetics, Walkersville, MD) supplemented with Single
Quots (Clonetics, San Diego, CA), transferrin (Sigma, St.
Louis, MO), isoproterenol (Sigma), and 400 g/ml G418 in
2% CO2. All of the other cell lines were purchased from
American Type Culture Collection (Rockville, MD) and
maintained in 10% fetal calf serum, DMEM F12 in 5% CO2.
The PI3K inhibitor, LY294002, and all other chemicals were
purchased from Sigma. IGF-1 (des- IGF-1; GroPep, Ade-
laide, Australia) was added at a concentration of 100 ng/ml
in serum-free DMEM F12. The responsiveness of the
184htrt cells to IGF-1 was confirmed by cell growth assays
(communicated by Dr. Michael Pollak, McGill University ).
Furthermore, we observed that the cells did not undergo
apoptosis following the withdrawal of serum over a 24-hour
period (data not shown). There was no evidence of cells
detaching from the plate or changes in cellular morphology.
Microarray Hybridizations and Analyses
The 184htert cells (1108/150 mm dish) were treated
without or with IGF-1 for 2, 4, 6, and 24 hours. The plating
density was selected so that the cells were 95% to 100%
confluent. The RNA was isolated using Qiagen Midi Kit
(Qiagen, Valencia, CA). Detailed protocols for microarray
methods and procedures are available at the website http: / /
dir.niehs.nih.gov/microarray. Briefly, total RNA was isolated
from each sample with a Qiagen Midi Kit. An in-house–
generated cDNA microarray chip (Toxchip v 1.0) was used
for gene expression profiling experiments [34]. A complete
listing of the genes on this chip is available at this website,
http: / /dir.niehs.nih.gov/microarray/chips.htm. cDNA micro-
array chips were prepared according to DeRisi et al. [35].
The spotted cDNA were derived from IMAGE clones that
covered the 30 end of the gene and ranged in size from 500 to
2000 bp. M13 primers were used to amplify insert cDNA from
purified plasmid DNA in a 100-l polymerase chain reaction
(PCR) reaction mixture. A sample of the PCR products
(10 l ) was separated on 2% agarose gels to ensure quality
of the amplifications. The remaining PCR products were
purified by ethanol precipitation, resuspended in ArrayIt
buffer (Telechem, San Jose CA), and spotted onto poly-L -
lysine–coated glass slides using a modified, robotic DNA
arrayer (Beecher Instruments, Bethesda MD). Total RNA
(35 g) was labeled with Cy3- and Cy5-conjugated dUTP
(Amersham, Piscataway, NJ) by reverse transcription (RT)
reaction and hybridized to the cDNA microarray. Each RNA
pair was hybridized to a total of three arrays with a fluor
reversal, meaning that for one array the control was labeled
with the Cy3 dye, and for two arrays it was labeled with Cy5.
The same RNA source was used for each of the replicates.
The cDNA chips were scanned using an Axon Scanner
(Axon Instruments, Foster City CA). A custom script has
been implemented in the Axon software to allow autobalanc-
ing of the two channels. The raw pixel intensity images were
analyzed using the ArraySuite v1.3 extensions of the IPLab
image processing software package (Scanalytics, Fairfax,
VA). This program uses methods that were developed and
previously described by Chen et al. [36] to locate targets on
the array, measure local background for each target and
subtract it from the target intensity value, and to identify
differentially expressed genes using a probability -based
method. We have previously determined that significant
autofluorescence of the gene features on the array,
attributed to spotting solution, occurs at high scanning
power. We measured the pixel intensity level of ‘‘blank’’
spots comprised of spotting solution. The data were then
filtered to provide a cut off at the intensity level just above the
blank measurement values to remove from further analyses
those genes having one or more intensity values in the
background range. After pixel intensity determination and
background subtraction, the ratio of the intensity of the IGF-
stimulated cells to the intensity of the control was calculated.
The ratio intensity data from a panel of 72 control genes ( list
available at http: / /dir.niehs.nih.gov/microarray/datasets)
were used to fit a probability distribution to the ratio intensity
values and estimate the normalization constants (m and c )
that this distribution provides. The constant, m, which
provides a measure of the intensity gain between the two
channels, ranged from 0.8 to 1.2 for all arrays, indicating that
the channels were approximately balanced near a value of
1.0. For each array, the ratio intensity values were
normalized to account for the imbalance between the two
fluorescent dyes by multiplying the ratio intensity value bym.
The other constant, c, estimates the coefficient of variation
for the intensity values of the two samples. All arrays in this
analysis had a c value of 0.2 or less. The probability
distribution that is fit to the data was used to calculate a 95%
confidence interval for the ratio intensity values. Genes
having normalized ratio intensity values outside of this
interval were considered to be differentially expressed. The
list of differentially expressed genes at the 95% confidence
level was created and deposited into the NIEHS MAPS
database [37]. Genes were only submitted to the list if they
were differentially expressed in at least two of three replicate
experiments. Any of these genes that indicated fluor bias or
high variation were not considered for further analysis.
Assuming that the replicate hybridizations are independent,
a calculation using the binomial probability distribution
indicated that the probability of a single gene appearing on
this list when there was no real differential expression is
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approximately 0.007. Finally, hierarchical cluster analysis
was carried out with the Cluster /TreeView package [38] to
group genes by the similarity of their gene expression
changes over time. The data were also analyzed using
GeneSpring (Silicon Genetics, Redwood City, CA) to
examine gene expression profiles across time and to identify
clusters of genes that exhibit similar expression patterns.
The entire dataset is available at the website http: / /
dir.niehs.nih.gov/microarray/datasets. The numbers next
to the gene name are the corresponding IMAGE consortium
clone identification number.
To assess the stability of gene expression for the control
cells, the pixel intensity values for the control samples were
compiled from each array. After transforming to the log2
scale, each value was standardized using the mean and
standard deviation of all log intensity values on that array.
Averaging the standardized log intensities for replicates gave
a 19204 matrix of values, where the rows represent all
genes on the array and the columns represent the four time
points. The similarity of the controls at the four time points
can be measured by considering the correlation of the
averaged log intensity values for the four times. The column
of values for the 2-hour time point was compared to each of
the other times using Pearson correlation, and the results
were as follows:
These correlation coefficients indicate that there is good
agreement between the control intensities at 2 hours and
each of the subsequent times.
Protein and mRNA Validations
Real -Time Fluorogenic RT-PCR (TaqMan) The 184htert
cells (1108 /150 mm dish) were treated without or with
IGF-1 for 0, 0.5, 1, 2, 4, 6, 8, and 24 hours and the RNA was
isolated as described above. RNA was then reverse-
transcribed in a 9600 GeneAmp PCR system using a
TaqMan Reverse Transcription Reagents Kit (Perkin-Elmer
Applied Biosystems, Foster City, CA). VEGF165 primers and
probes were chosen using Primer Express Software
(Perkin-Elmer Applied Biosystems).
Primers and Probe for VEGF165
Forward primer: 50-TGTGAATGCAGACCAAAGAAAGAT-30.
Reverse primer: 50-TCAGAGCGGAGAAAGCATTTG T-30.
Probe: 50 -AGCAAGACAAGAAAATCCCTGTGGGCC-30.
VEGF165 primers (300 nM), VEGF165 fluorogenic dual -
labeled probe (100 nM), 10-l aliquots of cDNA sample, and
2 TaqMan Universal PCR Reaction Mix were added
together, yielding a reaction volume of 50 l. Amplification
was carried out in an ABI Prism 7700 Sequence Detector. To
degrade any contaminating genomic DNA, the AmpErase
UNG enzyme was activated at 508C/2 min. The samples
were then subjected to a hotstart, 958C/10 min followed by
denaturation 958C/15 sec, then annealing and extension
was carried out at 608C/1 min for a total of 40 cycles. TATA
box-binding protein (TBP) mRNA was measured as a
housekeeping gene according to the recommended protocol
for this predeveloped assay reagent (PDAR; Perkin-Elmer
Applied Biosystems). Quantification of c- fos, IL -1B, fas
ligand, cyp 1A1, and cyp1B1 was performed using PDARs.
Each data point was replicated four times. The data were
analyzed by comparing the threshold cycle number or C t. A
lowerC t value indicates more template mRNA in the sample.
The C t values were normalized by subtracting target geneC t
values from the TBP C t values. The resulting numbers were
taken to the exponent of 2, to reflect the fact that PCR
doubles the amount of template every cycle.
VEGF and urokinase plasminogen activator (uPA) Protein
Determinations
The 184htert, MDA-MB-231, MDA-MB-436, MDA-MB-
435, MDA-MB-453, BT474, Hs578T, MDA-MB-175, MDA-
MB-157, and HBL100 cells were plated at a density of 5104
in a 96-well dish. Prior to exposure to IGF-1, they were
rinsed with PBS and serum-starved for 24 hours. The
conditioned medium was collected from IGF-1 treated and
untreated cells for 24 hours and stored at 808C. The
VEGF165 ELISA assay was performed according to the
manufacturer’s instructions (R&D Systems, Minneapolis,
MN), except that the conditioned medium was not diluted.
uPA protein in the conditioned media taken from the 184htert
cells was measured using a commercially available kit
(American Diagnostica, Greenwich, CT) previously
described [39].
Western Blots
The 184htert cells (1108/150 mm dish) were plated in
T150 culture flasks. The following day, the cells were rinsed
with PBS and placed in serum-free DMEM F12 for 24 hours.
The next day, cells were treated without or with IGF-1 at 2, 4,
6, and 24 hours. These were the same conditions used to
treat the cells for RNA isolations. We also used the same
passage number for protein and RNA analyses. Cells were
harvested by scraping and homogenizing in four packed cell
volumes of ice-cold lysis buffer [10 mM HEPES (pH 7.9),
1.5 mM MgCl2, 10 mM KCl, 1 mM EDTA, 0.1% NP-40, 0.5
mM DDT, 1 mM Na3VO4, 20 g/ml aprotinin, 2 g/ml
leupeptin, 2 g/ml pepstatin, 1 mM NaF, 400 M (4-
amidinophenyl ) -methanesulfonyl fluoride (APMSF)]. The
cell lysates were centrifuged at 10,000g for 2 minutes at 48C
and the resulting cytoplasmic extracts were snap- frozen in
liquid nitrogen and stored at 808C. The pellets were
resuspended in one PCV of nuclear lysis buffer [0.42 M
NaCl, 20 mM HEPES (pH 7.9), 1.5 mMMgCl2, 0.5 mM DTT,
400 MAPMSF, 2 g/ml leupeptin, 2 g/ml pepstatin, 2 g/
ml aprotinin, 1 mM NaVo4, 1 mM NaF], and mixed every 10
minutes for a total of 40 minutes. Nuclear debris was
removed by centrifugation at 14,000g for 10 minutes at 48C.
Extracts were snap- frozen in liquid nitrogen and stored at
Time points compared Pearson correlation
2 hours/4 hours 0.9271
2 hours/6 hours 0.9389
2 hours/24 hours 0.9209
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808C until analyses were performed. Western blot analysis
was performed as previously described [21] with the
exception of the following modifications. P-AKT, P-CREB,
and CREB were detected by polyclonal antibodies according
to the manufacturer’s instructions (New England Biolabor-
atories, Beverly, MA). The HIF-1 antibody (OZ12 clone)
was purchased from Neomarkers (Freemont, CA).
In Silico Promoter Analyses
We used a collection of public databases to find tran-
scription factor -binding sites. These databases included the
transcription regulatory regions database (www.mgs.bionet.
nsc.ru/mgs/dbases/trrd4/), eukaryotic promoter database
(www.epd.isb-sib.ch), pubmed and genebank provided
through the National Center for Biotechnology Information
(www.ncbi.nlm.nih.gov). The MatInspector (http: / /genoma-
tix.gsf.de/ ) was queried for query promoters that were not
previously mapped.
Results
Profiling of Genes Differentially Expressed by IGF-1
Differential gene expression was evaluated by comparing
184htert cells treated with or without IGF-1 for 2, 4, 6, and 24
hours using cDNA microarray. We found 156 (8%) of the
known genes and 24 (1.2%) expressed sequence tags
(ESTs) changed out of a total of 1920 with IGF-1 treatment.
The genes were categorized into six functional groups:
cancer progression, transcription factors, cell cycle, signal
transduction, extracellular matrix, and metabolism (Table 1).
We found it intriguing that IGF-1 regulated many genes
involved in cancer progression. A remarkable number of the
genes have defined roles in angiogenesis (Table 1); genes
indicated in bold). The significance of changes in genes
related to angiogenesis is discussed below. Additional
details of the genes that are differentially regulated by
IGF-1 can be viewed at http: / /dir.niehs.nih.gov/micro-
array/datasets / . IGF-1 also differentially regulated several
genes important for cell growth and the inhibition of
apoptosis. The complex regulation of cell growth was
exemplified by the fact that IGF-1 stimulated the expression
of cell cycle genes that promote proliferation (cyclin -
dependent kinase 7 and notch 4 ). IGF-1 also downregulated
genes that suppress cell growth such as ephrin-1A and
wee-1. The regulation of genes involved in apoptosis was
similarly complex where IGF-1 induced genes that prevent
apoptosis (peripheral type benzodiazepine receptor and
myeloid leukemia cell differentiation protein, MCL-1 ) and
suppressed genes that promote apoptosis ( fas ligand, FAST
kinase, cytochrome c oxidase, and BCL-2 interacting killer ).
We also noticed that several genes were differentially
regulated at multiple time points, thus providing evidence
for sustained regulation. For example, fas ligand was
negatively regulated at the 2- , 6- , and 24-hour time points.
There were also cases where a different portion of the same
gene was spotted on the chip as indicated by different
accession numbers. In all of the cases, hybridization
occurred in both cDNA and the relative effect of IGF-1 on
the expression of the gene was the same, e.g., BCL-2
interacting killer, fas ligand, PTEN, Jun B, insulin- induced
protein-1, and Metallothionein, thus providing cross-valida-
tion of the microarray process. The summation of these
results suggests that IGF-1 signaling has a broad influence
on many cellular processes that could contribute to cancer
progression.
We confirmed the expression of c- fos, VEGF, IL1B,
cyp1A1, cyp1B1, and fas ligand by TaqMan analyses at 0, 1,
2, 4, 6, 8, and 24 hours because these genes are reported to
be involved in cancer progression. Additional time points
were added to further define the regulation of these genes by
IGF-1. The induction of c- fosmRNA by IGF-1 at the 2-hour
exposure was confirmed by TaqMan. Both techniques
revealed a three- fold induction, while the additional time
point at 1 hour showed an 11- fold induction of c- fos mRNA
by IGF-1 (Figure 2A ). The quantification of genes repressed
by IGF-1 (cyp1A1, cyp1B1, and fas ligand ) by TaqMan was
consistent with the relative changes in mRNA found by
microarray (Figure 2B ). A probe for the VEGF165 splice
variant was used to expand our initial observation that IGF-1
induced VEGF mRNA by microarray analysis. The VEGF165
splice variant was selected because it positively regulates
angiogenesis in breast tumor xenografts [40]. We found that
using TaqMan, VEGF165 mRNA was induced 3.0- , 7.8- ,
5.8- , 6.6- , and 5.9- fold at 1, 2, 4, 6, and 8 hours,
respectively (Figure 2A ). In addition, induction of the
VEGF165 protein by IGF-1 was confirmed in the conditioned
media taken from 184htert cells treated with IGF-1 for 0, 2, 4,
6, and 24 hours (data not shown). To further support these
findings, a panel of breast cancer cell lines was screened for
the induction of VEGF165 protein by IGF-1. The induction of
VEGF165 protein was relatively widespread, with the most
notable changes occurring in the highly malignant cell lines
MDA-MB-231, MBA-MB-435, and Hs578T (Figure 2C ).
Finally, we validated the induction of uPA protein by ELISA.
There was approximately four - fold more uPA protein in the
conditionedmedia from cells treated with IGF-1 compared to
the untreated controls after 24 hours (data not shown).
These data are in support of a previous study where IGF-1
induced uPA in breast cancer cells [39].
Temporal Profiling of Nuclear Proteins Following IGF-1
Treatment
In addition to characterizing genes that are differentially
regulated by IGF-1, we followed a signal transduction
pathway connecting the cytoplasm to the nucleus. We chose
the PI3K/AKT pathway because of our interest in the role of
AKT in mediating gene expression. Treatment of 184htert
cells with IGF-1 resulted in the nuclear translocation of P-
AKT protein at 2, 4, 6, and 24 hours (Figure 3A ). The
sustained activation of P-AKT correlated with the regulation
of several genes that are known to be dependent upon the
PI3K/AKT pathway. Some of the genes regulated by AKT
include: peripheral benzodiazepine receptor, cyclooxyge-
nase-2, fas ligand, breast carcinoma fatty acid synthase, v-
myc, uPA, VEGF, myeloid cell leukemia-1, and L-myc (see
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Table 1. The Effect of IGF -1 on Gene Expression.
GenBank Description Time (hr ) Mean ratio
Cancer progression
N70825 Amphiphysin (Stiff -Mann syndrome in breast cancer ) 6 2.49
BCL2 - interacting killer 2 1.09
AA576942 BCL2 - interacting killer 2 1.06
H12940 Breast carcinoma fatty acid synthase 2, 4, 6 0.67, 0.54, 0.56
AA044993 Connective tissue growth factor ( IGFBP-8 ) 24 0.47
R80217 Cyclooxygenase 2 (hCox 2 ) gene 2 1.73
AA045731 Early growth response protein - 1, TGFB - inducible 2 1.93
AA081126 Ephrin A1 tyrosine kinase ligand 2, 4, 6 0.61, 0.46, 0.50
AA494493 Fas ligand; TNF ligand 2, 24 1.13, 0.660
AA477173 Fas ligand; TNF ligand 6 0.54
R89170 Focal adhesion kinase 2, 4, 6, 24 0.71, 0.39, 0.46, 0.55
R20750 FOS oncogene 2, 24 3.02, 0.56
W81586 Gardner -Rasheed feline sarcoma viral ( v fgr )
homolog of src2
4, 24 2.68, 5.67
AA054552 GRO1 oncogene (melanoma growth - stimulating activity, alpha ) 6 0.51
AA057188 GT198 2 1.59
N98757 Hepatic angiopoietin - related protein 2 1.43
W46413 Inhibitor of DNA binding - 3 2 1.50
AA040602 Insulin - like growth factor binding protein - 3 2 0.71
R50354 Leukemia inhibitory factor ( cholinergic differentiation factor ) 2, 24 2.24, 0.46
W47073 Leukemia virus receptor 1 (GLVR1 ) 2, 4 1.92, 1.92
W49497 MMP 1 ( interstitial collagenase ) 4, 6 3.42, 1.9
AA079861 MMP 9 (gelatinase B ) 4 2.32
AA017648 MCL1 (myeloid leukemia cell differ protein ) 2 1.59
T84055 Ovarian cancer downregulated myosin heavy
chain homolog (Doc1 )
2 1.87
AA056606 Peripheral - type benzodiazapine receptor 2, 4, 24 1.41, 2.09, 2.18
T49159 Plasminogen activator inhibitor, type II ( arginine serpin ) 24 0.55
N98421 PTEN 2 1.57
W37864 PTEN 2 1.16
N68057 Telomeric repeat -binding factor 1 4, 6 0.51, 0.57
W49722 Tissue inhibitor of metalloproteinase 2 24 0.58
T86483 Transferrin 4 2.37
N47476 Transmembrane 4 superfamily member 1 2, 4, 24, 0.65, 0.49, 0.59
AA487893 Transmembrane 4 superfamily member 1 4, 24 0.49, 0.58
AA115151 Tumor -associated calcium signal transducer 2 6, 24 0.58, 0.52
AA040727 uPA 2, 6, 24 1.51, 0.55, 0.53
AA148025 uPA receptor 2, 24 1.85, 0.60
W87741 v -myc avian oncogene 2, 6 1.99, 1.78
W19225 Vascular endothelial growth factor 2 1.53
R62813 v -myc 1 2, 4 0.64, 0.51
T87495 Zinc alpha -2 glycoprotein; ZAG 2 1.48
Transcription factors
AA053239 A20 DNA-binding protein, NFKB inhibitor 2 1.64
W87473 CCAAT box -binding transcription factor 1 6 1.61
AA004524 Cleavage and polyadenylation spec factor, 160 - kDa subunit 4 1.88
W46792 DP2 (Humdp2 ) 24 1.81
T89996 Fos - related antigen 1 ( fra1 ) 2 2.54
H91734 GA-binding protein transcription factor, beta subunit 1 ( 53 kDa ) 4 1.91
R31442 GATA-binding protein 3 2 0.62
AA503220 Jun B 2 2.08
W46228 Jun B 2 1.81
R41791 LIM domain kinase 1 2, 4 0.96, 2.26
R77770 Nuclear receptor coactivator 2 4 0.50
AA046245 Osteoblast - specific factor 2 (OSF 2p1 ) 2, 4, 6 0.62, 0.45, 0.53
AA011627 POU domain, transcription factor 2 2 1.60
AA115165 Stat 3 2 1.15
W95433 Steroid hormone receptor, NER 4 2.04
W70150 SW1 /SNF– related chromatin regulator 24 1.73
H83548 Transcription elongation factor B (SIII ), elongin A 24 0.48
W45393 Transcription factor ATF 7 4 1.98
R67075 Zinc finger protein, (ZFX putative transcription activator ) 2, 4 1.07, 1.32
AA043478 Zinc finger protein, homologous to mouse Zfp 36 2 1.51
Cell cycle
W80586 CDC46 homolog 2 1.03
AA031961 CDK7 2, 4, 6 0.46, 0.47, 0.59
N64843 CDK inhibitor 3 24 1.71
AA113188 GADD45 B 2, 4, 6 0.67, 0.47, 0.61
Notch 4 2 1.90
(continued on next page)
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Table 1. (continued)
GenBank Description Time (hr ) Mean ratio
AA740551 PMS4 homolog mismatch repair protein 2 1.21
AA026057 Thyroid autoantigen 70 kDa (ATP -dependent DNA helicase II ) 24 2.72
AA039640 WEE1- like tyrosine kinase 2, 4 0.33, 0.45
Signal transduction
H43049 Activin receptor - like kinase 1 4 2.24
AA045331 ADP ribosylation factor 4 - like, G -protein coupled 2 1.74
AA143571 cAMP -dependent protein kinase, type 1, alpha 2 1.31
R78286 CD94 antigen; killer cell lectin - like receptor 2 1.14
N70450 Coagulation factor II ( thrombin ) receptor 6 0.50
T79330 Complement factor H - related gene 3 2 1.42
W49546 Cytokine - inducible kinase 2 2.19
W19215 Decay accelerating factor for complement (CD55 ) 4 0.48
W65461 Dual specificity phosphatase 5 2 1.77
AA056608 Dual specificity phosphatase 10 2 0.70
W72792 Ephrin receptor, EphB2 2 1.66
AA074202 Epidermal growth factor receptor substrate 15 2 1.14
R84974 Fibroblast growth factor receptor 3 24 1.87
AA045013 G protein alpha - inhibiting activity polypeptide 2 2, 6 0.66, 0.61
R25530 GABA A receptor, Alpha 1 2 1.09
R35346 GABA A receptor, Alpha 5 2 1.12
H63532 GABA A receptor, epsilon subunit 2 0.67
AA053124 Heparin -binding EGF - like growth factor 2 2.40
AA084517 HSP40 homolog 2 0.55
AA046719 Insulin - induced gene 1; INSIG1 2, 4 1.64, 2.11
AA007569 Insulin induced gene -1; INSIG1 2 1.97
R39575 Interleukin 1 receptor, type II 4 3.02
W47225 Interleukin 1, beta 2, 4 2.21, 1.97
H43839 Latent transforming growth factor beta binding protein 2 24 0.60
AA055059 MacMarcks 24 0.58
AA034481 Mannose -6 -phosphate receptor 2 0.69
R59864 MAP kinase phosphatase 3; DUSP6 2 2.18
AA055467 Ornithine decarboxylase 1 2 1.39
R15351 Protein kinase C binding protein 2 0.67
AA005215 Protein kinase C delta 2 1.41
H84974 Protein kinase, cAMP -dependent, regulatory, type II, beta 6, 24 1.70, 2.28
N50894 Protein tyrosine phosphatase, receptor type, Z polypeptide 1 6 1.71
AA047066 PTEN - induced putative kinase 1 6 0.59
N23875 Serine / threonine protein kinase 4; Krs2 4, 6 1.93, 1.75
N77456 Serum /glucocorticoid– regulated kinase; SGK 2, 6 0.58, 0.56
N56944 Thioredoxin reductase I 2, 6 0.70, 0.56
AA187644 Thioredoxin reductase I 6 0.58
H51007 Tyrosine phosphatase ( IA 2 /PTP) 24 1.92
R07707 Tyrosine phosphatase nonreceptor - type, 1 2, 4, 6, 24 1.96, 2.54, 1.92, 1.83
AA053973 Ubiquitin conjugating enzyme (E2B) 6 0.55
Extracellular matrix
AA100382 Amyloid beta (A4 ) precursor protein 2, 6 1.03, 1.17
H44575 BPAG1 (plectin ) 2, 4, 6 0.62, 0.52, 0.51
R54968 Collagen, type XVI, alpha 1 2, 4, 6, 24 1.68, 2.34, 2.13, 2.03
AA159273 Collagen, type VII, alpha 6 0.53
AA069027 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA 2 receptor ) 6 0.52
AA001432 Laminin alpha 3 (LamA3 ) 24 0.49
AA076664 Laminin, beta 3 ( nicein (125 kDa ), kalinin ( 140 kDa ) 24 0.63
AA055478 Laminin, alpha 4 4 2.50
AA055637 S100A2 6 0.59
Metabolism
AA040600 AMP-activated protein kinase, gamma 1 subunit 6, 24 0.59, 0.28
AA054748 Aldehyde dehydrogenase 6 24 0.38
W79785 Aldehyde dehydrogenase 8 24 2.57
T62755 Apolipoprotein A 1 precursor; APOA1 4 0.54
R63185 Apolipoprotein E receptor 2 4, 6 2.20, 1.60
Corticosteroid binding globulin 24 1.70
AA418907 Cytochrome P450 IA1 4 0.43
N98684 Cytochrome c oxidase subunit VIc 24 0.61
AA040872 Cytochrome P450 IB1 (dioxin inducible ) 4, 6 0.44, 0.54
H05935 Cytochrome P450, subfamily XXVII A 2, 4, 6 1.72, 1.24, 1.28
AA574223 Glutathione reductase 2 1.15
(continued on next page)
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Table 1) for temporal comparisons). It was noted that these
genes were differentially expressed throughout the 24-hour
time course and these data correlated with the presence of
P-AKT in the nucleus. These data provide a temporal
association between P-AKT and gene expression. Next, we
investigated the relationship between stimulation of the
nuclear transcription factors, HIF-1 and P-CREB, because
these transcription factors regulate some of the genes
validated above, e.g., c - fos, cyp1A1, cyp1B1, and VEGF.
We found that IGF-1 stimulated the translocation of HIF-1
into the nucleus at the 4- and 6-hour time points (Figure
3B ). These data were compared to genes with known HIF-
1–responsive elements (HRE) in their promoter regions.
There was a general trend toward the presence of HIF-1
and the regulation of genes with an HRE (VEGF, transferrin,
thioredoxin reductase, cyp1A1, and cyp1B1 ). The genes
with an HRE were induced at the 4- and 6- hour time points
(see Table 1), although VEGF165 was an exception to this
generalization. Instead, we found that the temporal profiling
of VEGF and HIF-1was not coordinately regulated by IGF-
1 in this model system. This point is illustrated by the fact that
VEGF165 was induced much earlier than could not be
accounted for by the presence of HIF-1. The TaqMan data
showed that VEGF mRNA was induced by three- fold in the
first hour of exposure to IGF-1 (Figure 2A ). Therefore, we
suspected that other transcription factors such as CREBmay
be responsible for the early induction of VEGF by IGF-1.
This is possible because CREB not only binds to CRE sites
but it also has an affinity for HRE [41] and AP-1 consensus
sequences [42]. To test this hypothesis, we followed CREB
Table 1. (continued)
GenBank Description Time (hr ) Mean ratio
H65189 Glycogen synthase kinase -3beta; GSK3B 4 2.28
AA004597 Heat shock protein 70 related protein 6 1.70
AA043817 Leptin receptor 2, 24 1.48, 0.54
T74249 Leptin receptor 6 0.60
T68228 Low density lipoprotein receptor - related protein 6 2 1.69
AA037443 Metallothionein 2A 6 0.55
W73203 Metallothionein 1e gene (MT 1e ) 6 0.56
H77597 Metallothionein 1H 6 0.60
N77931 N-acetylglucosaminidase, alpha (Sanfilippo disease IIIB ) 6 0.55
H25860 NAD(P )H dehydrogenase 24 1.68
AA025552 NADPH flavin reductase 6 0.60
AA046316 Phospholipid hydroperoxide; glutathione peroxidase 4 2, 6 0.68, 0.50
H84974 Protein kinase, cAMP dependent, regulatory, type II, beta 4 2.52
H25590 Serum amyloid protein precursor 4, 24 0.53, 0.56
W45418 S -adenosylmethionine decarboxylase 4 1.86
H11561 Thioredoxin reductase 1 4, 6 0.6, 0.52
EST and others
EST 2 1.26
T90376 EST 2, 6 1.61, 1.09
W73510 EST 4 0.49
AA058510 EST 4 0.55
R10161 EST 4 2.09
AA010416 EST 4, 24 0.64, 0.57
AA039870 EST 6 2.13
W84634 EST 4 1.91
H79617 Est 2, 4, 6 0.69, 0.55, 0.53
R83223 EST 4 1.32
AA058704 EST similar to MAP kinase phosphatase I 6 0.62
R97218 EST similar to TVHUME 2, 4 1.09, 1.35
R39317 EST similar to tyrosine kinase receptor, ephrin B3 2 1.62
EST, clone ID 530030 6 1.33
H98630 EST, hypothetical protein FLJ20287 6 1.69
T66824 EST, similar to complement C3b /C4b receptor - like precursor 6 1.67
AA081098 EST, similar to GA binding protein beta 2 chain 2 1.05
H73129 EST, similar to p300 /CBP 4 3.26
W85846 EST, similar to IL1 receptor accessory protein precursor 2, 6 1.83, 2.00
W24201 ESTs similar to ROS1 oncogene 6 1.70
R01478 ESTs, moderately similar to I78855 serine / threonine–specific protein kinase 4, 24 2.12, 1.94
Histone deacetylase 3 2 1.68
N47581 Imprinted in Prader -Willi syndrome 2 1.17
AA044722 Signal sequence receptor, beta 2 1.54
R79560 Tight junction protein 1 ( zona occludens 1 ) 2, 4 1.52, 1.44
AA035626 Vacuolar sorting protein 33B 6 0.61
Microarray analysis of genes differentially expressed in the presence of IGF -1 at 2, 4, 6, and 24 hours. The genes that were differentially expressed were
organized into functional groups: cancer progression, transcription factors, cell cycle, signal transduction, extracellular matrix, and metabolism. Several expressed
sequence tags were also differentially regulated by IGF -1. In an effort to focus on some of the salient features of our microarray results, only the genes involved in
cancer progression are illustrated. It was noted that several genes in this functional group are also linked to angiogenesis (bold ). The entire gene list is available as
supplemental material (www.pnas.org ). The mean calculated ratios were only presented if they were considered statistically significant ( details in the Materials
and Methods section ).
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over time and found that IGF-1 stimulated the phosphor-
ylation of CREB at a peak of 1 hour (Figure 3C ). Next, we
examined whether AKT was responsible for the activation of
CREB. To this end, we inhibited AKT with LY294002 and
showed that CREB was no longer phosphorylated in cells
treated with IGF-1 for 1 hour (Figure 3D ). Finally, we
noticed that coincident with the presence of nuclear P-
CREB, the majority of genes possessing a cAMP-respon-
sive element (CRE) were also induced at the 2-hour time
point (early growth response gene-1,myeloid leukemia cell -
1, uPA, plasminogen activator -1, Jun B, cyclooxygenase-2,
c-myc, and c- fos ).
Promoter Analysis of IGF-1–Regulated Genes
The temporal regulation of gene expression was further
investigated by an extensive in silico promoter analysis. We
surmised that genes with similar expression profiles could be
Figure 2. (A ) The differential expression of genes involved in cancer
progression. Gene expression c - fos, VEGF - IL1B fas ligand, cyp1A1 and
cyp1B1 wasmeasured by TaqMan after 0, 0.5, 1, 2, 4, 6, 8, and 24 hours in the
absence or presence of IGF -1. Each time point was replicated four times and
the target gene expression was normalized to the TBP and A represents ones
that were induced by IGFI while panel B illustrates repression. (C ) Induction of
VEGF165 protein by IGF -1 measured in a panel of breast cancer cell lines.
VEGF165 protein was measured in breast cancer cells serum- free (SF ) or
with des - IGF -1. The conditioned medium was collected from each of the cell
lines 24 hours after the addition media containing or des - IGF -1. *Indicates
that there was a significant difference between the SF and IGF -1 treatment for
each cell line, P .05, Student’s t - test.
Figure 3. Temporal profiling of nuclear P -AKT, HIF - 1, and P -CREB. (A )
IGF -1 stimulated the nuclear translocation of P -AKT after 2, 4, 6, and 24
hours in the 184htert cells. The controls for this experiment were SK -N -MC
cells treated with forskolin ( positive ) and without forskolin (negative ). Neither
of the controls received IGF -1. (B ) Temporal profiling of HIF - 1 in the
absence or presence of IGF -1. IGF -1 stimulated the translocation of HIF - 1
at the 4 - and 6 -hour time points. (C ) Temporal profiling of P -CREB. IGF -1
was added to the 184htert cells for 0, 1, 3, and 6 hours and the protein extracts
were evaluated for P -CREB ( top panel ) and total CREB (bottom panel ).
CREB was maximally phosphorylated after 1 hour following IGF -1 treatment
while there was no effect on ATF -1. The total amount of CREB protein was
the same between time points (bottom panel ). (D ) Inhibition of AKT signal
transduction with LY294002 (30 M) inhibited the phosphorylation of CREB
by IGF -1. Cells were pretreated with LY294002 for 10 minutes then IGF -1
was added for 1 hour. Desferrioxamine (DXF, 100 M) was added to the cells
for 1 hour as a positive control for p -CREB. An equal volume of dimethyl
sulfoxide (DMSO) served as a vehicle control for the LY294002 compound.
There was no inhibition of P -CREB in the presence of DMSO and IGF -1.
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regulated through common regulatory sequences. The
genes were organized based upon their pattern of expres-
sion by cluster analysis [38]. We noted that gene expression
was clustered to the following nodes: 1) induced, 2)
repressed, or 3) induced then repressed (Figure 4 ). Next,
we searched the 50 untranslated regions and observed that
the majority of the genes that were consistently induced have
CRE/AP-1/AP-2 coupled with SP-1 and ETS transcription
factor -binding sites in their promoters (Table 2). In contrast,
the genes that were repressed commonly had FKHR, myc,
and WT-1 binding sites. These data are supported by
evidence that myc negatively regulates CYP1A1 [43],
GADD45 [44], and GAS [45], while WT-1 suppressed the
expression of connective tissue growth factor [46]. The
regulation of the genes that were transiently induced then
repressed also had common regulatory regions in their
promoter. Most of the genes in node C had either a CRE
and/or AP-1/AP-2 binding site in the promoter. These data
describe putative composite elements that are common
among coordinately expressed genes.
Gene expression is commonly regulated by the tran-
scription factors we focused upon. For example, many of the
genes on the microarray have CRE or AP-1 binding sites on
their promoter. What was not immediately obvious was why
IGF-1 did not change their expression. To delve into this
issue, we randomly selected 10 genes that were not
differentially regulated by IGF-1 in our microarray experi-
ments. The gene list was cross-referenced to http: / /
dir.niehs.nih.gov/microarray/chips.htm to confirm that they
were indeed part of the ToxChip repertoire. Then we se-
arched the literature to determine how the genes were
regulated. We also use MatInspector software by Genomatix
when the promoter was not sequenced. In this case, the
gene was mapped to its chromosomal location using
National Center for Biotechnology Information, Map Viewer
(http: / /www.ncbi.nlm.nih. gov/ cgi -bin/Entrez/hum_srch?
chr=hum_chr.inf&query), the start site was identified, then
we selected 300 bp upstream for our promoter analyses using
MatInspector. We found that although the unregulated genes
had common transcription factor -binding sites such as CRE
and AP-1, the expression of these genes depended upon
methylation or acetylation (Table 3). Furthermore, many of
the genes were located in DNAse 1-hypersensitive sites,
suggesting that alteration of chromatin structure is required
for transcription. We summarize these data by concluding
that IGF-1 induces some genes and not others based on
whether or not they require methylation for expression.
Discussion
IGF-1–responsive gene expression changes were inves-
tigated in immortalized breast epithelial cells over time. In
this study, we found that 8% of the known genes and 1.2%
of the ESTs were differentially regulated by IGF-1. The
changes in gene expression also correlated with the
presence of the nuclear proteins P-AKT, HIF-1, and P-
CREB. An in-depth analysis of the clustering data revealed
that genes that were similarly expressed had distinct
transcription factor-binding sites. A similar study reported
a correlation between single transcription-binding sites and
gene expression in yeast [35]. Our study is the first
example of coupling promoter regulation to gene expression
profiles in mammalian cells. We noted that there were
composite elements that characterized coordinately
expressed genes. These data therefore provide a frame-
work for understanding how some genes are regulated by
Figure 4. Hierarchical clustering of genes differentially expressed at 2, 4, 6, and 24 hours. There were three major nodes found, which represent genes that were (A )
induced, (B ) repressed, or (C ) induced then repressed. The genes that were induced were assigned a pseudo - color of red and those that were repressed were
assigned a green color. The numbers next to the gene names indicate the clone identification. A complete view of the dendrogram is available at http: / /
dir.niehs.nih.gov /microarray / datasets / .
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IGF-1. To extend the interpretation of these data, these
trends could be applied to understanding how previously
uncharacterized genes are regulated. For example, the
ELKL kinase is a serine threonine protein kinase for which
the promoter has not been previously studied. ELKL kinase
clusters with MCL-1, STAT3, and v-myc and these genes
Table 2. Promoter Analysis of IGF -1–Regulated Genes.
Gene Cre AP-1 AP -2 SP -1 HIF -1 NFkB ETS FKHR EGR-1 CCAAT Myc WT-1 OCT-1 p53
Node A: induced
ADP ribosylation factor 4 * * * *
Aldehyde dehydrogenase *
Apoliprotein E receptor 2 * *
ATF -1 * * * *
Cyclooxygenase 2 * * * *
Cytochrome P450 XXVII * * *
Fibroblast growth factor receptor 3 * *
Heat shock protein - 40 *
Heparin binding epidermal growth factor * * *
Insulin - induced protein 1 * *
Interleukin 1b * *
MMP 1 * *
MMP 2 * *
Metallothionein *
Transferrin * *
Tyrosine phosphatase 1B *
uPA * * *
uPA receptor * * * *
Vascular endothelial growth factor * * *
Node B: repressed
Apoliprotein A 1 precursory *
Casein kinase 2y * *
Connective tissue growth factor * * *
Cytochrome P450 1A1 * *
Fas ligandy * * *
GADD45 * * * *
Growth arrest specific protein *
MMP-2 inhibitory *
Serum amyloid A protein precursor * * *
Node C: induced / repressed
Early growth response gene -1 *
Fos related antigen - 1y * *
MAP kinase phosphatase - 1 *
Myeloid leukemia cell differ. protein - 1 *
Plasminogen activator inhibitor I * * *
Plasminogen activator inhibitor II *
STAT3 *
V - fos * *
V -myc *
yIndicates genes clustered outside of this node, but were negatively regulated by IGF -1.
In silico promoter analysis of IGF -1– induced genes. The 50 untranslated region of each promoter was evaluated for transcription factor - binding site. This is a
compilation of putative and experimentally validated sites. These data were compared to the clustering analysis for correlations between temporal gene expression
and the presence of transcription factor - binding sites.
Additional data are available at our website, http: / / dir.niehs.nih.gov.microarray / datasets
Table 3. Regulation of Genes that were not Differentially Following IGF -1 Treatment.
Gene Regulation Reference Expression depends upon
BRCA-1 Cre [ 55 ] Methylation
Catalase CCAAT, ERG-1, SP -1, NF -Y [ 56 ] Acetylation?
Estrogen receptor -alpha AP -2, CpG islands, [ 57 - 59 ] Methylation
Glutathione S- transferase pi AP -1, SP -1, CpG islands [ 60 - 62 ] Methylation
Gycogen synthase kinase -alpha AP -1, YY -1, LSF, MZF -1, SP -1, CRE [63 ] Unknown
Multidrug resistance -1 AP -1, YB -1, CCAAT [64,65 ] Methylation
Topoisomerase II CCAAT, Acetylation [ 66 ] Acetylation
Topoisomerase III SP -1 (4 ), YY -1, USF -1 [ 67 ] Methylation
In silico promoter analysis of genes that were printed on the microarray chip but not induced by IGF -1. Eight genes were randomly selected from our gene list and
their promoters were queried for transcription factor - binding sites. Although many of the promoters had common transcription factor - binding sites such as CRE
and AP -1, their expression depended upon methylation.
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all have a CRE site in their promoters (Node C). Therefore
it is reasonable to predict that this ELKL kinase is similarly
regulated by CREB. Finally, this approach could also apply
to understanding the regulation of known genes for which
the promoter regulatory regions are not yet mapped. We
used a combination of public databases and only found
promoter regulatory maps for 36/156 of the known genes.
Thus, there is still a vast gap in our knowledge of how many
human genes are regulated.
Our study of the gene expression profiling of immortalized
breast epithelial cells derived from the 184 parental cell line
complements two previously published microarray reports
that used the same parental cell line. In the first case,
comparisons of gene expression were made between 184
cells and tumor cell lines by SAGE (serial analysis of gene
expression) and microarray technologies [47]. In the second
case, the 184 cells were used in a comparison between cell
lines (normal versus cancer) and breast tissues (normal
versus cancer) [33]. In both of these reports, S100A2 and
bullous pemphigoid antigen (BPAG) were lost in breast
cancer cell lines and tumors. Similarly, we found that IGF-1
negatively regulated S100A2 and BPAG. These reported
changes could be permissive for premalignant cells to
become invasive because the S100A2 protein is involved in
organization of the cytoskeleton and the inhibition of cellular
migration [48]. Likewise, BPAG is a protein that organizes
into hemidesmisomes and connects epithelial cells to the
basement membrane. Disorganization of hemidesmisomes
occurs in DCIS and this cytoarchitectural feature is com-
monly lost in invasive breast cancer [49]. These data
suggest that there is a loss of the basement membrane that
could facilitate the conversion of DCIS to invasive cancers.
Thus, BPAG and S100A2 are examples of genes negatively
regulated by IGF-1 and are differentially expressed during
cancer progression. Our data complement other gene
expression databases by providing a possible mechanism
for some of the observed changes. This compendium of
relevant microarray databases to will inevitably enrich our
understanding of breast cancer progression.
One of the goals of this study was to gain insight into
potential mechanisms whereby IGF-1 relates to the risk of
developing cancer. A mechanistic approach will help us to
bridge the current gaps in translational research as it relates
to IGF-1 and breast cancer. As an example, epidemiological
studies indicate that elevated serum IGF-1 levels in
premenopausal women are linked with increased mammo-
graphic density [50]. Furthermore, it is well known that high
breast density is linked to a significant increase in the risk of
developing breast cancer, but the biological basis for this
association remains unknown. A few features of dense
breasts are clear though, these tissues are characterized by
an accumulation of stromal and epithelial cells. To address a
possible cause for these events, it was recently shown that
local tissue levels of IGF-1 and total collagen proteins are
elevated in dense breast tissues [51]. We now have
evidence that IGF-1 consistently induces collagen XVI at
the 2- , 4- , 6- , and 24-hour time points. Given these data,
we propose that endocrine and/or paracrine IGF-1 could
stimulate the production of collagen XVI protein, thereby
making the breast denser and masking the identification of
small tumors. This is a testable hypothesis that will warrant
further investigation.
IGF-1 can also contribute to the progression of cancer by
promoting cell growth, inhibiting apoptosis, and stimulating
invasion/metastasis. One of the conclusions that emerged
from our microarray data was that IGF-1 induced many
genes involved in angiogenesis. We found this of interest
because angiogenesis is an essential process for the growth
and metastasis of tumors [52]. The importance of angio-
genesis in breast cancer progression is underscored by the
fact that this process is evident in preinvasive lesions such as
DCIS [53]. Several studies point toward VEGF as a potent
mitogen for endothelial cells ( reviewed in Ref. [54] ). We
found that IGF-1 induced VEGF mRNA in premalignant
breast epithelial cells and in most breast cancer cell lines.
Hence, IGF-1 could contribute to vascularization through
VEGF, but this vascular mitogen does not stand alone as the
only angiogenic factor that is important for neovasculariza-
tion. We found that IGF-1 induced genes that positively
regulate angiogenesis, including cyclooxygenase 2, uPA/
uPAR, FGFR, transferrin, matrix metalloproteinase-1,
matrix metalloproteinase-2, angiopoietin -1, interleukin B1,
and the ephrin B2 receptor. In addition, many genes that
inhibit angiogenesis were also repressed by IGF-1, including
tissue inhibitor of matrix metalloproteinase-2, plasminogen
activator inhibitor -1, plasminogen activator inhibitor -2, and
protease inhibitor -1. The synchronous expression of genes
that positively regulate angiogenesis suggests functional
complementation. Ephrin B2 receptor and angiopoietin-1
regulate neovascularization by stimulating vessel maturation
and sprouting, whereas VEGF, uPA/uPAR, and the MMPs
are involved in the proliferation and migration of new blood
vessels. The observation that IGF-1 regulates many differ-
ent genes involved in angiogenesis necessitates finding
common molecular pathways. Furthermore, understanding
such pathways could lead to novel cancer intervention
strategies that would inhibit classes of genes involved in
angiogenesis rather than targeting single gene products. The
expression profiling data and the characterization of nuclear
events triggered by IGF-1 reported in this study will provide
valuable insight into the regulation of cancer progression and
common signal transduction pathways that control angio-
genesis.
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